secwatch.observer — SEC 8-K summary
======================================

Issuer:     QuidelOrtho Corp (QDEL)
CIK:        0001906324
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001906324-24-000025
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

QuidelOrtho appoints Brian J. Blaser as CEO effective May 6, 2024
-----------------------------------------------------------------

- Blaser, ex-Abbott EVP Diagnostic Products, replaces interim CEO Michael Iskra and interim President Robert Bujarski.
- He receives $1M base salary, annual target cash bonus of 125% of base, and equity grants totaling $10M.
- Board expanded to 11 members; Blaser joins as director effective May 15, 2024.
- Interim Office of the CEO dissolved; Iskra and Bujarski return to prior executive roles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1906324/000190632424000025/0001906324-24-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1906324/000190632424000025/qdel-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001906324-24-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer